Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: INC Research/inVentiv Health | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: INC Research/inVentiv Health

Combined Clinical Solutions Segment generated revenue of $533.4 million in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

INC Research/inVentiv Health
3Q Revenues: $822.3 million (+110%)
3Q Loss: $148 million (earnings were $27.3 million 3Q16)
YTD Revenues: $1.6 billion (+32%)
YTD Loss: $123.4 million (earnings were $75.1 million YTD16)
Comments: INC Research completed the merger with inVentiv Health on August 1, 2017. Service revenue in the quarter was up 128% due to the Merger, partially offset by a decline in revenues due to continued customer and regulatory delays. Combined Clinical Solutions Segment generated revenue of $533.4 million in the quarter. Combined Commercial Solutions Segment generated revenue of $233.2 million. Results include the impact of Merger-related transaction expenses of $84.3 million and $108.1 million, respectively, an impairment charge of $30 million in 3Q17, and an increase in amortization expense of $41.9 million in both periods due to the acquisition of intangible assets as a result of the Merger.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters